OncoMatch

OncoMatch/Clinical Trials/NCT06523673

Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer

Is NCT06523673 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies second-line systemic therapy for metastatic non-small cell lung cancer.

Phase 3RecruitingSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06523673Data as of May 2026

Treatment: second-line systemic therapyThe goal of this clinical trial is to learn if Stereotactic Body Radiotherapy (SBRT) can treat the oligo-progressive metastatic non-small cell lung cancer (NSCLC) after first-line chemotherapy. The main questions it aims to answer are: Does SBRT improve progression-free survival in oligo-progressive metastatic non-small cell lung cancer after first-line chemotherapy? Does SBRT improve overall survival and quality of life in oligo-progressive metastatic non-small cell lung cancer after first-line chemotherapy? Researchers will compare SBRT in combination with standard of care (SOC) and SOC only to see if SBRT works to treat oligo-progressive metastatic non-small cell lung cancer after first-line chemotherapy. Participants will: Take SBRT in combination with SOC or SOC only. Visit the clinic for checkups and tests as required by the study. Keep a diary of their symptoms and complete the quality of life assessment questionnaire.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Biomarker criteria

Allowed: ALK fusion

Allowed: EGFR mutation

Disease stage

Required: Stage IV

Metastatic disease required

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Min 1 prior line

Must have received: chemotherapy — first-line

Patients who had prior first-line chemotherapy with clinical benefit lasting for ≥3 months.

Cannot have received: investigational drug or device

have been treated with another investigational drug or investigational device that may affect this study within 4 weeks prior to first treatment

Lab requirements

Blood counts

normal bone marrow function

Kidney function

normal internal organ function

Liver function

normal internal organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify